Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Drug Discovery,Biochemistry,Biotechnology
Link
http://link.springer.com/article/10.1007/s13238-017-0400-z/fulltext.html
Reference208 articles.
1. Ahmed N, Brawley V, Diouf O, Anderson P, Hicks J, Wang L, Dotti G, Wels W, Liu H, Gee A et al (2014) Abstract 3500: T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma. Cancer Res 72(8 Supplement):3500
2. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A et al (2015) Human epidermal growth factor receptor 2 (HER2)—specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33(15):1688–1696
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116
4. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA (2011) Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Therapy 22(12):1575–1586
5. Barrett DM, Grupp SA, June CH (2015) Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol (Baltimore, Md : 1950) 195(3):755–761
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advancements and Challenges in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28
2. Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy;Advances in Cancer Immunotherapy [Working Title];2024-05-15
3. Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review;Frontiers in Oncology;2024-01-23
4. Programmable synthetic receptors: the next-generation of cell and gene therapies;Signal Transduction and Targeted Therapy;2024-01-03
5. Microphysiological systems for solid tumor immunotherapy: opportunities and challenges;Microsystems & Nanoengineering;2023-12-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3